Novel strategies that co-target immune system priming for both PSA and prostatic acid phosphatase (PAP) in early stage disease could maximize the immune response to recognize the biomarkers associated with PC progression prior to the enhanced immunosuppressive TME correlated with late stage disease. The gene discussed is ACP3; the disease is pachyonychia congenita.